RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on PTC Therapeutics (NASDAQ:PTCT) but has reduced the price target from $27 to $22.
January 26, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained a 'Sector Perform' rating on PTC Therapeutics and lowered the price target from $27 to $22, indicating a potential downside compared to the previous target.
The reduction in price target by RBC Capital suggests that the analyst sees less upside potential for PTC Therapeutics, which could lead to negative sentiment among investors and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100